| Literature DB >> 27862341 |
Simen W Schive1,2,3, Aksel Foss1,2,3, Afaf Sahraoui1,2,3, Kristine Kloster-Jensen1,2,3, Geir Hafsahl4, Gunnar Kvalheim5, Torbjørn Lundgren6, Bengt von Zur-Mühlen7, Marie Felldin8, Ehab Rafael9, Marko Lempinen10, Olle Korsgren11, Trond G Jenssen1,12, Vinod Mishra13, Hanne Scholz1,2,3.
Abstract
Islet transplantation is a minimally invasive β-cell replacement strategy. Islet transplantation is a reimbursed treatment in Norway. Here, we summarize the cost and clinical outcome of 31 islet transplantations performed at Oslo University Hospital (OUS) from January 2010 to June 2015. Patients were retrospectively divided into three groups. Thirteen patients received either one or two islet transplantation alone (ITA), while five patients received islet transplantation after previous solid organ transplantation. For the group receiving 2 ITA, Kaplan-Meier estimates show an insulin independence of 20% more than 4 years after their last transplantation. An estimated 70% maintain at least partial graft function, defined as fasting C-peptide >0.1 nmol L-1 , and 47% maintain a HbA1c below 6.5% or 2 percent points lower than before ITA. For all groups combined, we estimate that 44% of the patients have a 50% reduction in insulin requirement 4 years after the initial islet transplantation. The average cost for an islet transplantation procedure was 347 297±60 588 NOK, or 35 424±6182 EUR, of which isolation expenses represent 34%. We hereby add to the common pool of growing experience with islet transplantation and also describe the cost of the treatment at our center.Entities:
Keywords: cost; islet transplantation; outcome; type 1 diabetes
Mesh:
Year: 2016 PMID: 27862341 DOI: 10.1111/ctr.12871
Source DB: PubMed Journal: Clin Transplant ISSN: 0902-0063 Impact factor: 2.863